University of British Columbia
Improving diagnosis and care of familial hypercholesterolemia : from genetic testing to outcomes
Abstract
dc:descriptionFamilial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) from birth and increased risk of premature atherosclerotic cardiovascular disease (ASCVD). FH is typically caused by pathogenic variants in LDLR, APOB, and PCSK9. Despite effective lipid-lowering therapies, FH remains underdiagnosed and undertreated, particularly in Canada where access to genetic testing is limited. The genetic spectrum of FH in multi-ethnic populations and the utility of genetic testing for patients with premature acute coronary syndrome (ACS) remain incompletely characterized. This thesis aimed to provide evidence to improve the diagnosis and clinical management of FH in British Columbia (BC) by addressing two questions: (1) What is the diagnostic yield and genetic variant spectrum of FH within the BC FH Registry? and (2) Does FH genetic testing for patients hospitalized with premature ACS improve rates of diagnosis, lipid-lowering therapy and LDL-C management? For the first objective, genetic and clinical data from 1278 individuals in the BC FH Registry were analyzed. Pathogenic/likely pathogenic variants were identified in 476 individuals (37.2%), primarily in LDLR (96.4%), followed by APOB (6.9%) and PCSK9 (0.6%). Overall, 187 unique variants, including 90 recurrent variants, were identified, demonstrating allelic heterogeneity consistent with a multi-ethnic population. Among 106 families with a genetically confirmed index case, 133/253 relatives (53%) were positive, and at least one affected relative was identified in 73.6% of families. Positive relatives were younger, had lower LDL-C levels and less definitive clinical FH than positive index cases, supporting cascade testing. The second objective evaluated FH genetic testing in the prospective Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) study of ACS patients <60 years old with elevated LDL-C. Among 100 patients tested, 8% had an FH-causing variant. Genetic testing increased definite FH diagnoses from 0% in the control phase to 10% in the intervention phase and was associated with lower follow-up LDL-C, greater LDL-C target attainment, and increased statin and statin-ezetimibe use. This thesis demonstrates that genetic testing improves FH diagnoses, enables cascade testing, and aids clinical management in high-risk patient populations, thus supporting broader implementation in BC and similar healthcare systems.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Medical Genetics
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Vaizman, Nicol
- Contributors dc:contributor
-
- Brunham, Liam
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/95074